CTCBIO Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
May 12, 2023 at 03:14 am EDT
Share
CTCBIO Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was KRW 0.00032 million compared to KRW 0.0003 million a year ago. Net loss was KRW 1,711.32 million compared to net income of KRW 6,750.01 million a year ago.
Basic loss per share from continuing operations was KRW 72 compared to basic earnings per share from continuing operations of KRW 287 a year ago. Diluted loss per share from continuing operations was KRW 72 compared to diluted earnings per share from continuing operations of KRW 287 a year ago. Basic loss per share was KRW 72 compared to basic earnings per share of KRW 287 a year ago.
CTCBIO Inc. is a Korea-based company engaged in the manufacture and marketing of pharmaceuticals, veterinary drugs, animal feed supplements and functional foods. It pharmaceuticals include anticancer agents, antibiotics, bone injury treatments, antiulcer agents, blood flow stimulants and others. Its veterinary drugs include vaccines, antibiotics, immune enhancers, enzymes, organic acid, avian influenza-related agents and others. Its animal feed supplements include pigments, kapok seed meal, sesame meal and others. Its functional food business includes the development and manufacture of enzymes, lactobacillus and related products mainly used in dairy products. It also involves in the development of pharmaceutical manufacturing technology and know-how. The Company distributes its products within domestic market and to overseas markets.